Literature DB >> 31182533

In Vitro Activity of Bedaquiline and Delamanid against Nontuberculous Mycobacteria, Including Macrolide-Resistant Clinical Isolates.

Dae Hun Kim1, Byung Woo Jhun1, Seong Mi Moon1, Su-Young Kim1, Kyeongman Jeon1, O Jung Kwon1, Hee Jae Huh2, Nam Yong Lee2, Sung Jae Shin3,4,5, Charles L Daley6,7, Won-Jung Koh8.   

Abstract

We evaluated the in vitro activities of the antimicrobial drugs bedaquiline and delamanid against the major pathogenic nontuberculous mycobacteria (NTM). Delamanid showed high MIC values for all NTM except Mycobacterium kansasii However, bedaquiline showed low MIC values for the major pathogenic NTM, including Mycobacterium avium complex, Mycobacterium abscessus subsp. abscessus, M. abscessus subsp. massiliense, and M. kansasii Bedaquiline also had low MIC values with macrolide-resistant NTM strains and warrants further investigation as a potential antibiotic for NTM treatment.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  Mycobacterium abscessus; Mycobacterium avium complex; Mycobacterium kansasii; bedaquiline; delamanid; nontuberculous mycobacteria

Mesh：

Substances：

Year:  2019        PMID： 31182533      PMCID： PMC6658790          DOI： 10.1128/AAC.00665-19

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  39 in total

1.  In Vitro Susceptibility Testing of Bedaquiline against Mycobacterium abscessus Complex.

Authors:  Barbara A Brown-Elliott; Richard J Wallace
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

Review 2.  An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases.

Authors:  David E Griffith; Timothy Aksamit; Barbara A Brown-Elliott; Antonino Catanzaro; Charles Daley; Fred Gordin; Steven M Holland; Robert Horsburgh; Gwen Huitt; Michael F Iademarco; Michael Iseman; Kenneth Olivier; Stephen Ruoss; C Fordham von Reyn; Richard J Wallace; Kevin Winthrop
Journal:  Am J Respir Crit Care Med       Date:  2007-02-15       Impact factor: 21.405

3.  Clinical Characteristics and Treatment Outcomes of Patients with Acquired Macrolide-Resistant Mycobacterium abscessus Lung Disease.

Authors:  Hayoung Choi; Su-Young Kim; Dae Hun Kim; Hee Jae Huh; Chang-Seok Ki; Nam Yong Lee; Seung-Heon Lee; Soyoun Shin; Sung Jae Shin; Charles L Daley; Won-Jung Koh
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

Review 4.  Treatment of Mycobacterium avium Complex (MAC).

Authors:  David E Griffith
Journal:  Semin Respir Crit Care Med       Date:  2018-08-02       Impact factor: 3.119

5.  Clinical Characteristics and Treatment Outcomes of Patients with Macrolide-Resistant Mycobacterium massiliense Lung Disease.

Authors:  Hayoung Choi; Su-Young Kim; Hyun Lee; Byung Woo Jhun; Hye Yun Park; Kyeongman Jeon; Dae Hun Kim; Hee Jae Huh; Chang-Seok Ki; Nam Yong Lee; Seung-Heon Lee; Sung Jae Shin; Charles L Daley; Won-Jung Koh
Journal:  Antimicrob Agents Chemother       Date:  2017-01-24       Impact factor: 5.191

6.  In Vitro Activity of Bedaquiline against Nontuberculous Mycobacteria in China.

Authors:  Yu Pang; Huiwen Zheng; Yaoju Tan; Yuanyuan Song; Yanlin Zhao
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

7.  Mechanisms of resistance to delamanid, a drug for Mycobacterium tuberculosis.

Authors:  Mamoru Fujiwara; Masanori Kawasaki; Norimitsu Hariguchi; Yongge Liu; Makoto Matsumoto
Journal:  Tuberculosis (Edinb)       Date:  2017-12-30       Impact factor: 3.131

Review 8.  Epidemiology of Nontuberculous Mycobacteriosis.

Authors:  Jennifer Adjemian; Shelby Daniel-Wayman; Emily Ricotta; D Rebecca Prevots
Journal:  Semin Respir Crit Care Med       Date:  2018-08-02       Impact factor: 3.119

Review 9.  Advances in the management of pulmonary disease due to Mycobacterium abscessus complex.

Authors:  W-J Koh; J E Stout; W-W Yew
Journal:  Int J Tuberc Lung Dis       Date:  2014-10       Impact factor: 2.373

Review 10.  Meta-analyses and the evidence base for microbial outcomes in the treatment of pulmonary Mycobacterium avium-intracellulare complex disease.

Authors:  Jotam G Pasipanodya; Deborah Ogbonna; Devyani Deshpande; Shashikant Srivastava; Tawanda Gumbo
Journal:  J Antimicrob Chemother       Date:  2017-09-01       Impact factor: 5.790
View more
  16 in total

1.  Differential In Vitro Activities of Individual Drugs and Bedaquiline-Rifabutin Combinations against Actively Multiplying and Nutrient-Starved Mycobacterium abscessus.

Authors:  Jin Lee; Nicole Ammerman; Anusha Agarwal; Maram Naji; Si-Yang Li; Eric Nuermberger
Journal:  Antimicrob Agents Chemother       Date:  2021-01-20       Impact factor: 5.191

Review 2.  ERS International Congress 2021: highlights from the Respiratory Infections Assembly.

Authors:  Oliver W Meldrum; Kylie B R Belchamber; Kiarina D Chichirelo-Konstantynovych; Katie L Horton; Tetyana V Konstantynovych; Merete B Long; Melissa J McDonnell; Lidia Perea; Alberto L Garcia-Basteiro; Michael R Loebinger; Raquel Duarte; Holly R Keir
Journal:  ERJ Open Res       Date:  2022-05-23

3.  Efficacy of Fluoroquinolones as Substitutes for Ethambutol or Rifampin in the Treatment of Mycobacterium avium Complex Pulmonary Disease According to Radiologic Types.

Authors:  Jang Ho Lee; Yea Eun Park; Yong Pil Chong; Tae Sun Shim; Kyung-Wook Jo
Journal:  Antimicrob Agents Chemother       Date:  2021-12-20       Impact factor: 5.938

4.  In Vitro Bedaquiline and Clofazimine Susceptibility Testing in Mycobacterium abscessus.

Authors:  Bettina Schulthess; Fatma Nur Akdoğan Kittana; Rico Hömke; Peter Sander
Journal:  Antimicrob Agents Chemother       Date:  2022-04-14       Impact factor: 5.938

5.  Approach to the diagnosis and treatment of non-tuberculous mycobacterial disease.

Authors:  Kelly M Pennington; Ann Vu; Douglas Challener; Christina G Rivera; F N U Shweta; John D Zeuli; Zelalem Temesgen
Journal:  J Clin Tuberc Other Mycobact Dis       Date:  2021-05-08

Review 6.  Pipeline of anti-Mycobacterium abscessus small molecules: Repurposable drugs and promising novel chemical entities.

Authors:  Anna Egorova; Mary Jackson; Victor Gavrilyuk; Vadim Makarov
Journal:  Med Res Rev       Date:  2021-03-01       Impact factor: 12.388

7.  In Vitro Activity of Pretomanid against Nontuberculous Mycobacteria.

Authors:  Huiwen Zheng; Yiting Wang; Wencong He; Feina Li; Hui Xia; Bing Zhao; Shengfen Wang; Chen Shen; Yanlin Zhao
Journal:  Antimicrob Agents Chemother       Date:  2021-11-01       Impact factor: 5.938

8.  Successful bedaquiline-containing antimycobacterial treatment in post-traumatic skin and soft-tissue infection by Mycobacterium fortuitum complex: a case report.

Authors:  Johanna Erber; Simon Weidlich; Tristan Tschaikowsky; Kathrin Rothe; Roland M Schmid; Jochen Schneider; Christoph D Spinner
Journal:  BMC Infect Dis       Date:  2020-05-24       Impact factor: 3.090

Review 9.  Alternative and Experimental Therapies of Mycobacterium abscessus Infections.

Authors:  Michal Meir; Daniel Barkan
Journal:  Int J Mol Sci       Date:  2020-09-16       Impact factor: 5.923

Review 10.  Looking beyond Typical Treatments for Atypical Mycobacteria.

Authors:  Clara M Bento; Maria Salomé Gomes; Tânia Silva
Journal:  Antibiotics (Basel)       Date:  2020-01-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.